RSV prevention in all infants: which is the most preferable strategy?

S Esposito, B Abu Raya, E Baraldi, K Flanagan… - Frontiers in …, 2022 - frontiersin.org
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …

The road to approved vaccines for respiratory syncytial virus

TJ Ruckwardt - NPJ vaccines, 2023 - nature.com
After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved …

Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus

GL Lin, SB Drysdale, MD Snape, D O'connor… - Nature …, 2024 - nature.com
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory
infection in young children. RSV disease severity is known to be age-dependent and highest …

Respiratory syncytial virus infection in the modern era

M Ludlow - Current opinion in infectious diseases, 2023 - journals.lww.com
Respiratory syncytial virus infection in the modern era : Current Opinion in Infectious
Diseases Respiratory syncytial virus infection in the modern era : Current Opinion in …

Clinical, genomic, and immunological characterization of RSV surge in Sydney, Australia, 2022

GJ Walker, CSP Foster, A Sevendal… - …, 2024 - publications.aap.org
OBJECTIVES The 2022 seasonal respiratory syncytial virus (RSV) epidemic in Sydney,
Australia saw an unprecedented number of RSV detections. We aimed to characterize …

Host responses to respiratory syncytial virus infection

A Agac, SM Kolbe, M Ludlow, ADME Osterhaus… - Viruses, 2023 - mdpi.com
Respiratory syncytial virus (RSV) infections are a constant public health problem, especially
in infants and older adults. Virtually all children will have been infected with RSV by the age …

Clinical and biological consequences of respiratory syncytial virus genetic diversity

E Rios Guzman, JF Hultquist - Therapeutic Advances in …, 2022 - journals.sagepub.com
Respiratory syncytial virus (RSV) is one of the most common etiological agents of global
acute respiratory tract infections with a disproportionate burden among infants, individuals …

Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

HC Bergeron, RA Tripp - Expert Opinion on Investigational Drugs, 2022 - Taylor & Francis
Introduction Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory
tract infection (LRTI) in infants and young children. Palivizumab is an RSV-specific …

All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?

S Schaerlaekens, L Jacobs, K Stobbelaar, P Cos… - Vaccines, 2024 - mdpi.com
Respiratory Syncytial Virus (RSV) poses a significant global health concern as a major
cause of lower respiratory tract infections (LRTIs). Over the last few years, substantial efforts …

Clinical and viral factors associated with disease severity and subsequent wheezing in infants with respiratory syncytial virus infection

JP McGinley, GL Lin, D Öner… - The Journal of …, 2022 - academic.oup.com
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants and
young children worldwide. Here we evaluated host demographic and viral factors …